Retrosternal bypass operation for unresectable squamous cell cancer of the esophagus

Comparison of Short-term Outcomes Between Esophageal Bypass Surgery and Self-expanding Stent Insertion in Esophageal Cancer: A Propensity Score-matched Analysis Using a Large-scale Inpatient Database

BACKGROUND

Advanced esophageal cancer is occasionally accompanied by difficulty swallowing owing to esophageal stenosis or tracheoesophageal fistula formation. Esophageal bypass surgery and stent insertion are considered feasible palliative management options. The aim of this study was to evaluate the short-term outcomes of these palliative treatments.

MATERIALS AND METHODS

Patient data were obtained from a large-scale inpatient database of 42 National University Hospitals in Japan. Patients with advanced esophageal cancer who underwent esophageal bypass surgery or stent insertion between April 2016 and March 2021 were included in this study. One-to-one propensity score matching of patients who underwent bypass surgery or stent insertion was performed. The primary outcomes were time to diet resumption and length of hospital stay after surgery. The secondary outcome was the incidence of postoperative complications.

RESULTS

In 43 propensity score-matched pairs, the incidence of postoperative respiratory complications was significantly higher in the bypass group than in the stent group (32.6% vs. 9.3%, P = 0.008). Postoperative length of hospital stay was longer in the bypass group than in the stent group (24 vs. 10 d, P < 0.001). Logistic regression analysis revealed that stent insertion was associated with a decreased risk of respiratory complications (odds ratio 0.077, P < 0.007). Among patients who underwent the interventions (bypass surgery or stent insertion) and subsequently underwent anticancer therapy (chemotherapy/radiotherapy) during hospitalization, the interval between the intervention and anticancer therapy was longer in the bypass group than in the stent group (25 vs. 7 d, P = 0.003).

CONCLUSIONS

Esophageal stent insertion provides better short-term outcomes than bypass surgery in patients with advanced unresectable esophageal cancer.

Drainage Tubeless (DRESS) Bypass Surgery as the Best Palliative Care for Unresectable Thoracic Esophageal Cancer with and without Esophago-Respiratory Fistula

Approximately half of the patients with esophageal cancer are diagnosed at an advanced stage with inoperable disease. The technique of bypass surgery, which is one of the palliative procedures for esophageal cancer, usually requires the insertion of a drainage tube for clearing secretions from the blind remnant esophagus. Since the artificial drainage tube is sometimes problematic for the patient after discharge from the hospital, drainage tubeless (DRESS) surgery might be preferable. The authors demonstrated the utility of DRESS bypass surgery by adding esophagostomy in the right supraclavicular region in three patients with unresectable esophageal cancer with and without esophago-respiratory fistula. All patients had been able to take per-orally and discharged the hospital. Two of three patients are alive with per-oral intake at 1 year later. This DRESS bypass surgery technique, which has not hardly reported in the literature, could release the patients from the tube trouble after the discharge from the hospital and give the patients the better quality of life.

Role of stenting in the palliation of gastroesophageal junction cancer: A brief review

Gastroesophageal junction cancer has an increasing incidence in western countries. It is inoperable when first manifested in more than 50% of cases. So, palliation is the only therapeutic option for the advanced disease to relieve dysphagia and its consequences in weakened patients with an estimated mean survival under 6 mo. This article has tried to identify trends focusing on current information about the best palliative treatment, with an emphasis on the role of stenting. Self-expanding stent placement, either metal or plastic, is the main management option. However, this anatomical location creates some particular problems for stent safety and effectiveness which may be overcome by properly designed novel stents. The stents ensure a good quality of life and must be preferred over other alternative methods of loco-regional modalities, i.e., external radiation, laser thermal or photodynamic therapy. Although stent placement is generally a simple, safe and effective method, there are sometimes complications, increasing the morbidity and mortality rate. Bypass operative procedures have now been abandoned as a first choice. The stomach instead of the colon must be used for a bypass operation when it is needed. Chemotherapy, despite the toxicity, and intraluminal radiation (brachytherapy) have a well-defined role.

Tailoring esophageal cancer surgery

Esophageal cancer is a significant source of major mortality worldwide and is increasing dramatically in incidence. Without treatment this disease leads rapidly to death, but intervention also carries significant risk, so a carefully tailored approach must be used to maximize oncological efficacy while minimizing the negative consequences of intervention. Careful patient selection based on histologic and anatomic staging, consideration of each patient's clinical variables, appropriately timing chemo- and radiation therapy, and minimizing the morbidity of surgical intervention may significantly improve a patient's chances of surviving this disease, but each must be carefully orchestrated with a tailored approach to treatment. This review will serve as a guide to tailoring surgery for esophageal cancer.

Palliative therapy for patients with unresectable esophageal carcinoma

Most patients diagnosed with carcinoma of the esophagus do not undergo therapy with curative intent. The focus of treatment for these patients is to maximize their progression-free survival and palliate the most common sequelae of their disease: dysphagia, malnutrition, pain, and intraluminal tumor bleeding. This article discusses the available treatment options for palliation of patients with unresectable esophageal cancer.

Esophageal stenting for malignant and benign disease: 133 cases on a thoracic surgical service

BACKGROUND

Esophageal stenting is increasingly being utilized to treat a variety of benign and malignant esophageal conditions. The aim of our study was to review our experience with self-expanding metal, plastic, and hybrid stents in the treatment of esophageal disease on a thoracic surgical service.

METHODS

The study population consisted of 126 patients undergoing placement of 133 stents at a single institution from 2000 to 2008. Data were reviewed retrospectively for patient characteristics, indications, complications, reinterventions, and efficacy.

RESULTS

Most stents were placed for palliation of dysphagia due to advanced esophageal cancer (90 of 133; 68%) or extrinsic compression from lung cancer (13 of 133; 9.8%). A total of 123 self-expanding metal stents (SEMS), 7 self-expanding plastic stents (SEPS), and 3 hybrid stents were placed. Of the SEMS, 57 were uncovered and 66 were covered. Malignant obstruction was typically palliated with SEMS, while covered stents were chosen for perforations or anastomotic leaks. The median length of stay was 1 day. Complications occurred in 38.3% of stent placements, with a single perioperative mortality resulting from massive hemorrhage on postoperative day 4. Most complications resulted from stent impaction (12.8%), migration (9.7%), or tumor ingrowth (5.3%). Tumor ingrowth was uncommon with uncovered stents (2 of 57; 3.5%). Stent migration was common with SEPS (4 of 7; 57%), or hybrid stents (2 of 3; 67%). Survival was short in patients with underlying malignancy (median 104 days for esophageal cancer and 48 days for lung cancer), with 20% of patients surviving less than 1 month.

CONCLUSIONS

Esophageal stent placement is safe and reliable. The goals of therapy are typically met with a single intervention. The majority of patients require no further interventions, though life expectancy often is short and patient selection may be difficult. Most complications are due to stent obstruction, though stent migration is an issue particularly with SEPS and hybrid stents. Esophageal surgeons should be adept at stent placement.

Tubo gástrico isoperistáltico de grande curvatura gástrica com sutura mecânica no tratamento cirúrgico do câncer de esôfago irressecável

RACIONAL: Frequentemente, o diagnóstico da neoplasia do esôfago é tardio, restando como escolha terapêutica o tratamento paliativo. A transposição de tubo isoperistáltico da grande curvatura gástrica é um dos métodos de eleição que, porém, quando complicado com a deiscência da anastomose, impede a alimentação natural, comprometendo a qualidade de vida. OBJETIVO: Avaliar as complicações da anastomose esofagogástrica cervical com sutura mecânica com o tubo gástrico, em pacientes com câncer de esôfago irressecável. MÉTODO: Vinte e dois pacientes com câncer de esôfago irressecável foram submetidos à transposição do tubo gástrico isoperistáltico. A anastomose com o coto esofágico foi realizada com sutura mecânica circular em nível cervical. Foram avaliadas complicações sistêmicas (cardiopulmonares) e locais (a deiscência e a estenose da anastomose esofagogástrica cervical). RESULTADOS: Dez pacientes (45,5%) apresentaram de uma a três complicações, dos quais seis (27,2%) com complicações sistêmicas: um (4,5%) embolia pulmonar (evoluindo ao óbito), um infarto do miocárdio e quatro (18,2%) com infecção de pulmão (todos com boa evolução com o tratamento clínico. Cinco pacientes tiveram complicações locais: três (13,6%) com deiscência da anastomose e quatro (18,2%) com estenose da anastomose, sendo que dois deles tiveram deiscência prévia. De 20 pacientes avaliados em período de seis a 18 meses, 16 (80%) apresentaram deglutição satisfatória para sólidos e/ou pastosos. CONCLUSÃO: O tubo gástrico isoperistáltico de grande curvatura, com sutura mecânica, parece oferecer melhora significativa da deglutição com qualidade de vida satisfatória e morbimortalidade aceitável.

Palliation of malignant aerodigestive fistulae with self-expanding metallic stents

Malignant aerodigestive fistulae are rare but devastating sequelae of thoracic cancers, most commonly associated with esophageal cancer. Survival following development of a malignant aerodigestive fistula is measured in weeks. Palliation is the primary goal of therapy and to this end, we report the use of self-expanding metallic stents (SEMS) as treatment. Between May 1999 and January 2004, 12 patients were treated for malignant aerodigestive fistulae. The underlying diagnosis was esophageal cancer for 10 patients, and non-small cell lung cancer for two others. All patients were symptomatic and fistulae were diagnosed by esophagoscopy in seven, bronchoscopy in two, and esophagram in three. Seven covered Wallstents (seven esophageal) and eight covered Ultraflex (five tracheal and three esophageal) were used. A single stent was placed in eight patients (seven esophageal and one tracheal). Three patients required esophageal and tracheal stents and one patient needed two tracheal stents. General anesthesia was required in 50% of the patients. There were no procedure-related complications. Symptoms were palliated in 100% of patients and oral intake was reinstituted in 42% (5/12). All the patients were discharged from hospital after SEMS placement and one patient returned for an uneventful tracheal stent replacement secondary to mucus impaction 2 months later. SEMS placement is an effective strategy to palliate malignant aerodigestive fistulae. Complications are rare and symptoms are alleviated in most patients.

Esophageal bypass using a gastric tube and a cardiostomy for malignant esophagorespiratory fistula

Esophageal bypass with a gastric tube and a cardiostomy is a method recently devised for malignant esophagorespiratory fistula. This method separates completely the alimentary and respiratory tracts. Four patients underwent these procedures. No operative deaths occurred, nor was there any anastomotic leakage or disruption of the excluded esophagus. The average survival time was 7 months. However, all patients were allowed to consume food orally up to the last moment of life. This bypass procedure is simple and safe to perform, and is thus a feasible treatment choice for patients with such fistulas.

Postoperative Imaging of Esophageal Cancer: What Chest Radiologists Need to Know

A variety of surgical procedures are used in the treatment of esophageal cancer. These procedures include transthoracic esophagectomy (Ivor Lewis procedure, McKeown procedure, left thoracoabdominal approach), transhiatal esophagectomy, and various forms of bypass surgery. Although meticulous surgical techniques and improved postoperative care have markedly reduced the complications associated with these techniques, esophageal resection is still associated with various intraoperative complications (hemorrhage, injury to the tracheobronchial tree, recurrent laryngeal nerve injury) and postoperative complications (anastomotic leak; mediastinitis; respiratory problems, including pleural effusion, pneumonia, and acute respiratory distress syndrome; cardiac and functional complications). Postoperative tumor recurrence is not uncommon in patients undergoing curative resection for esophageal cancer and can be categorized as either locoregional (locoregional lymph node metastases, anastomotic recurrence) or distant (hematogenous metastases, pleural or peritoneal seeding). Hematogenous metastases most commonly involve the liver, lungs, and bones, followed by the adrenal glands, brain, and kidneys. Hematogenous metastases may also involve multiple organs simultaneously. The sophisticated surgical procedures used in esophagectomy can result in anatomic changes and confound image interpretation. The radiologist must understand how these procedures can affect imaging data and be familiar with the appearances of postoperative anatomic changes, complications, and tumor recurrence to ensure accurate evaluation of affected patients.

O tubo gástrico isoperistáltico no tratamento paliativo do câncer do esôfago

OBJETIVO: Avaliar os resultados da derivação esofagogástrica no câncer avançado do esôfago. MÉTODO: Foram estudados de forma retrospectiva 24 pacientes com carcinoma epidermóide de esôfago nos estádios III (66,66%) e IV (33,34%), submetidos à derivação esofagogástrica através da construção do tubo gástrico isoperistáltico da grande curvatura pela técnica de Postlethwait. RESULTADOS: Quanto à morbidade e mortalidade, os pacientes de média etária de 41,8 anos e linfócitos acima de 1.500/mm³ demonstraram taxas de complicações pós-operatórias inferiores àqueles com média de 54,09 anos. A fístula da anastomose, embora seja considerada comum (15 casos - 62,50%), apresentou evolução benigna e ocluiu espontaneamente em 14 casos. Não houve qualquer tipo de complicação cirúrgica pós-operatória em cinco casos (20,83%), o tempo médio cirúrgico foi de 285,77 minutos, e a mortalidade operatória de sete casos (29,17%). A sobrevida foi 4,19 meses. CONCLUSÕES: Em vista da ocorrência de complicações, que determinam altas taxas de morbidade e mortalidade, o tubo gástrico isoperistáltico é um método de tratamento cirúrgico que deve ser dirigido a pacientes selecionados, em especial àqueles com número alto de linfócitos e idade mais baixa.

Best palliation in esophageal cancer: surgery, stenting, radiation, or what?

Palliation of patients with obstructing or fistulizing esophageal cancer is not easy. Median survival cannot be expected to be longer than 3-6 months, regardless of which therapy is carried out. Self-expandable metal stents have revolutionized the treatment of these patients because of easy insertion, relatively low complication rates and reasonably good functional results. Plastic tubes are mainly indicated in situations in which removal may be needed. The palliative effect of external beam radiation is well established, endoesophageal brachytherapy having the advantage of delivering a high dose in a short time. More recently, there has been increasing interest in locally destructive therapies, mostly in combination with palliative radiation or radiochemotherapy. Obviously, a single best palliation for every situation does not exist. The most appropriate method to alleviate symptoms must be worked out for each individual patient depending on the specific patient situation and the specific expertise of the physician.